Practice and Patient Compliance on the PPI (Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South Korea

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the treatment profile of approximately 1,000 adult patients with gastroesophageal reflux who begin raberpazole sodium treatment for 4 months, and assess patients' adherence to the study drug.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Korea, Ltd., Korea
• Treatments: Proton Pump Inhibitors; Rabeprazole

Criteria

Inclusion Criteria:

• Patients complaining about heartburn or acid regurgitation, the typical GERD symptoms, more than once a week

• After a full explanation about the observational study, patients who fully understand it and sign a written consent form

Exclusion Criteria:

• Patients who took rabeprazole sodium within the last four weeks

• Patients who are hypersensitive to the active ingredient of rabeprazole sodium or benzimidazole

• Patient with other digestive tract diseases other than GERD (gastrointestinal cancer, liver disease, pancreatic disease, peptic ulcer, inflammatory digestive tract diseases [in case of ulcer, however, scars from healed ulcer may be included])

• Patients with other severe accompanying diseases including renal impairment, cerebrovascular disease, cardiovascular disease and severe respiratory disease

• Patients who must constantly take Proton Pump Inhibitors other than rabeprazole sodium during study period

• Pregnant or lactating women